7-hydroxymitragynine, marketed online and in smoke and vape shops as '7-OH', has become one of the most-discussed grey-market compounds on social media, promoted in tablets, gummies and liquid 'shots' as a legal, plant-derived way to manage pain, mood or opioid withdrawal. It is a minor alkaloid of the kratom plant (Mitragyna speciosa), but the products driving the trend are heavily concentrated or semi-synthetic, containing far more 7-OH than any leaf naturally provides.
The pharmacological reality is that 7-OH is an opioid. It is a potent agonist at the mu-opioid receptor and is generally described as substantially more potent than morphine at that receptor, and more potent than mitragynine, the leaf's main alkaloid. That is the basis for both the euphoria users report and the dependence, respiratory-depression and overdose concerns regulators cite.
In July 2025 the FDA recommended that the DEA control 7-OH as a Schedule I substance. On July 1, 2026 the DEA announced its intent to temporarily place 7-OH and three related substances — mitragynine pseudoindoxyl, MGM-15 and MGM-16 — into Schedule I, with a notice of intent published in the Federal Register in early July 2026. HHS and FDA publicly backed the action.
A critical detail often lost in the trend coverage: the scheduling is designed to target concentrated and chemically enhanced 7-OH above a specified threshold, not the kratom plant itself or conventional leaf products that fall below that concentration. Regulators have framed this as separating a natural-product debate from what they describe as an enhanced synthetic opioid being sold beside the register.
Because temporary scheduling actions can be challenged, delayed or finalised on shifting timelines, the exact effective date and threshold language should be checked against the current Federal Register entry rather than assumed from trend reporting.